Definitive Contract 75N93024C00044

Award Date 9/10/24
Potential Completion Date 9/9/25
Potential Value $300K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Irvine, CA 92618, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Immport Therapeutics Inc., doing business as Antigen Discovery Inc., for $30,000.00. The contract is for the provision of microarray products and services to support detection and response efforts related to pathogens such as monkeypox virus, Brucella, SARS-CoV-2, and Leptospirosis. Immport Therapeutics is a biotechnology company specializing in high throughput...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Immport Therapeutics Inc., doing business as Antigen Discovery Inc. The contract, valued at $15,000.00, is for the provision of falciparum custom protein microarrays. Immport Therapeutics is a biotechnology company that specializes in high-throughput protein microarray technology and related services, and has...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp, a small, Asian-Pacific American-owned biotechnology company based in Rockville, Maryland. The contract, valued at $98,958.95, is for the provision of various research and development services related to genetics, immunology, virology, and infectious diseases, including...
The Centers for Disease Control and Prevention (CDC) awarded a $200,000.00 firm fixed price purchase order to Immport Therapeutics, Inc., doing business as Antigen Discovery Inc., a biotechnology company specializing in protein microarray technology. The contract is for the identification of Brucella canis and B. abortus RB51 seroreactive proteins and the development of serology assays. This sole-source contract was awarded without a set-aside designation. Antigen Discovery has extensive...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...
This federal contract award is for site-directed mutagenesis services (Catalog #GI-M100) provided by Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, MD. The $9,994.40 firm fixed price contract was awarded on September 22, 2010 by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID). The contract has an ultimate completion date of September 30, 2010 and does not have a set-aside designation. Geneimmune Biotechnology Corp....
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $49,946.10 firm-fixed-price purchase order contract for antibody expression services to Biointron Biological USA Inc., a small disadvantaged business. The contract, which has no set-aside designation, has an ultimate completion date of July 11, 2025. The award was made on July 12, 2024. NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious and...
This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The contract has a potential value of $12,265.00 and is focused on DNA preparation services. The contract was set aside for small businesses and does not appear to be associated with a larger contract vehicle. Geneimmune...
This federal contract award, valued at $224,562.96, was made by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services' National Institutes of Health (NIH). The contract was awarded to Infotech Soft, Inc., a for-profit, woman-owned business, and is a Definitive Contract with a Firm Fixed Price. The work is to be performed in Miami, Florida and the contract has a completion date of July 31, 2018. This appears to be a Small...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...

This is a $300,000.00 firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Immport Therapeutics Inc., doing business as Antigen Discovery Inc. The contract is for SBIR 133 - ANTIGEN and has an ultimate completion date of September 9, 2025. Immport Therapeutics is a biotechnology company that specializes in protein microarray technology and related services to support infectious disease detection, monitoring, and research. The company has previously provided products and services to support federal efforts related to pathogens such as monkeypox, SARS-CoV-2, and Cryptosporidium under other federal contract and grant awards. This contract does not have a set-aside designation.

Generated 3/25/25, 9:51 AM